Browse Category


Clay Siegall Aims for the Best

Clay Siegall is an accomplished man who has not ceased in making success in his life. He is an entrepreneur as well as a philanthropist. As a philanthropist, he has changed the lives of various individuals as well as the society at large. Clay is well-known to be the CEO of Seattle Genetics, other than that he is also the president and co-founder of the firm. He achieved a Ph.D. from George Washington University in genetics and a B.S in Zoology from the University of Maryland. At the same university, Clay serves as a board member. Clay Siegall is not only a business man but also a scientist. He received an award as the alumnus of 2013 in natural sciences, math, and computer from Maryland University. Clay Siegall’s interest in science is in biotechnology.

Biotechnology is an area whereby different doctors gather together to conduct an analysis of drugs so that they can get an excellent treatment for cancer. As a result, Seattle Genetics has collaborated with various organizations to continue with the process of finding the best antibody drug conjugate (ADC). The victims of cancer are pleased with this project and hope that they will recover. So far, they have managed to create a drug by the name Adcetric and as a result, it has been able to reach over 60 countries.

The financial graph of Seattle Genetics is doing so much better due to the hard work of the staff members. The organization as now supplied more than 20 ADCs to various clinics. Furthermore, Seattle Genetics has achieved $330 since it began working. The patients of cancer are so far happy with the results of the firm and they are receiving good hospitality.

Apart from the mentioned drugs that the firm has created, it has also made SGN-CD33A. Acute myeloid is a type of cancer which has been able to receive this drug and fortunately it is working well. Seattle Genetics is encouraged with the progress of the medicines and they are more dedicated to producing better results for cancer therapy. The organization has linked up with similar firms to create more therapies to treat cancer.